Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Participants must have histlogically confirmed stage IV non-small cell lung cancer . * The initial treatment with gefitinib/icotinib evaluated PR/NC and the efficacy lasted for more than 6 months, then the disease progressed later. (The efficacy was assessed as PD according to the evaluation standard of RECIST1.1) * At least a measurable lesion that meets the RECIST 1.1 criteria. * Any gender. Age ≥18 years and ≤75 years * Life expectancy \>3 months. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Previously, EGFR gene test showed EGFR exon 19 deletion or exon 21 (L858R) mutation, and the gene test showed no T790M mutation before enrollment. * Adequate organ function: haemoglobin ≥ 90 g/L;neutrophils count ≥1.5×109/L; platelet count ≥ 90 × 109/L; total bilirubin ≤ 1.5 × ULN ;ALT \< 2 × ULN, (ALT \< 5 × ULN, for those with liver metastases);AST \< 2 × ULN, (AST \< 5 × ULN, for those with liver metastases); Cr≤1.5× ULN. * Echocardiography : LVEF≥50% * 12-leads electrocardiogram : QTcF\<450ms (man), \<470ms(woman) * Patient informed consent and signed written consent * Patient compliance was good and voluntary follow-up, treatment, laboratory testing, and other research steps were performed as planned. Exclusion Criteria: * The patient has previously received anti-tumor therapy for EGFR TKIs other than gefitinib and ectinib for lung cancer. * Patients that cannot detect EGFR gene, or patients with known T790M mutation. * Small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer). * CT or MRI shows that the tumor lesion is ≤ 5 mm from the large vessel, or there is a central tumor that invades the local large blood vessel; or there is a significant pulmonary cavity or necrotizing tumor. * Active brain metastasis, cancerous meningitis, spinal cord compression patients. * Other active malignancies that require simultaneous treatment. * Has a history of malignant tumors in the past 5 years. * Patients with previous anti-tumor treatment-related adverse reactions who have not recovered to NCI-CTC AE≤1. * Abnormal coagulation ,with bleeding tendency or undergoing thrombolysis or anticoagulant therapy. * Renal insufficiency: urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0g, or creatinine clearance \<60ml / min. * Severe acute or chronic infection requiring systemic treatment. * Suffering from severe cardiovascular disease: myocardial ischemia ,myocardial or arrhythmia. * Clinically significant hemoptysis occurred within 3 months prior to enrollment; or significant clinically significant bleeding symptoms or a clear tendency to hemorrhage. * Untreated active hepatitis : Hepatitis B or Hepatitis C